News for RGBP Stock

Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™ Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024 Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024 Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024 Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024 Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 7, 2023 Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023 Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly Regen BioPharma, Inc. Receives First Phase of Confirmatory Study Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. Regen BioPharma, Inc. to Present at the Emerging Growth Conference on October 5, 2023 Studies On Regen BioPharma, Inc.';s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 6, 2023 Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 22, 2023 Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023 Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023 Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio Regen BioPharma Appoints Two New Scientific Advisory Board Members Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022 Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022 Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine